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ABSTRACT 
 
 
 Protein kinase C ζ (PKCζ) is believed to be a promising target for the treatment of 
some diseases, including inflammatory diseases, obesity and diabetes. Hit identification 
of PKCζ inhibitors was conducted by structure-based modification, virtual screening and 
biological evaluation. Among all the compounds selected and synthesized, compound 
JW-1-60A showed moderate activity against PKCζ at 30 μM and 100 μM. The molecular 
modeling studies showed that the binding mode of JW-1-61A was very close to the 
binding mode of JP-3-149, a reported PKCζ inhibitor with very potent activity, which 
might partially explain the moderate activity of JW-1-61A. Based on the structure of JW-
1-60A, we will synthesize a series of its analogs and investigate their selectivity against 
other kinases in the future. 
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CHAPTER 1.    INTRODUCTION 
 
 
PKC Family 
 
 In 1977, protein kinase C (PKC) was first discovered from bovine cerebellum by 
Nishizuka’s group. They found this new kinase was able to phosphorylate histone [1]. 
One of his papers published two years later showed that PKC played an important role in 
cell surface signal transduction and tumor promotion. Besides activated by 
phosphatidylserine (PS), PKC was also activated by diacylglycerol (DAG) produced 
during the inositol phospholipids turnover [2]. Recently, the PKC family has been 
reported to consist of at least ten members, which are classified into three classes: 
conventional PKCs (α, βI, βII, γ), novel PKCs (δ, ε, μ, θ and η), and atypical PKCs (ζ and 
ι/λ) [3].  
 
 Most of conventional PKCs are selectively translocated to the plasma membrane 
due to their affinity for phosphatidylinositol 4, 5-bisphosphate (PIP2). This phospholipid 
plasma membrane generally has the negative charges on the surface, which is favorable 
for the recruitment of conventional PKCs. Conventional PKCs contain PKC-α (PRKCA), 
PKC-β1, β2 (PRKCB) and PKC-γ (PRKCG). Novel PKCs have the higher affinity for 
DAG containing membranes. Novel PKCs include PKC-δ (PRKCD), PKC-ε (PRKCE), 
PKC-η (PRKCH) and PKC-θ (PRKCQ). Conventional PKCs and novel PKCs both 
possess a C1 domain, which is responsible for binding to the DAG and phorbol 12-
myristate 13-acetate (PMA), and a C2 domain, which is involved in the calcium-
dependent phospholipid binding, and a serine/threonine-kinase domain (Figure 1-1). 
 
 Atypical PKCs (aPKCs) including ζ (PRKCZ), λ and ι (PRKCI) are a subfamily 
of PKC family which require neither Ca2+ nor DAG for activation. Unlike conventional 
PKCs and novel PKCs which possess two C1 domains (C1A and C1B domain) and C2 
domain, aPKCs have only one atypical C1 domain and PB1 domain instead. The PB1 
domain is responsible for the modular protein-protein interactions, resulting in the 
regulation of atypical PKCs [4].  
 
 
PKCζ and Diseases 
 
 
PKCζ and Inflammatory Diseases 
 
 Interestingly, aPKCs, including PKCζ and PKC ι/λ, are involved in distinct 
downstream signaling pathways. Lack of PKC ι/λ leads to the lethality of the mouse 
embryonic stem cells, while PKCζ deficiency severely impairs the activation of the NF-
κB pathway, causing the immunological deficiencies of the mice [5-6]. Jorge’s group 
found that PKCζ knockout cells showed much less phosphorylation of the RelA in 
response to tumor necrosis factor- α (TNF- α). Therefore, they concluded that PKCζ was 
able to phosphorylate RelA. They also believed Ser311, whose phosphorylation is  
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Figure 1-1. Structure domains of cPKC, nPKC and aPKC 
 
 
Cat Domain 
Cat Domain 
Cat Domain 
C1A C1B 
C1A C1B 
C1 
C2
C2
PB1
cPKC: α, βI, βII, γ 
nPKC: δ, θ, ε, η 
aPKC: ξ, τ/λ 
 3 
required for the interaction of RelA and the co-activator CREB-binding protein(CBP), 
plays a critical role in phosphorylation of RelA in NF-κB  transcriptional activation [7]. 
So far extensive studies have been reported that PKCζ is involved in the activation of NF- 
κB pathway in various cell types, such as B-cells, T helper cells [6, 8-11]. As a result, 
PKCζ has been proposed as a novel target for treating inflammatory disease such as 
sepsis [12], psoriasis [13] and asthma [9]. 
 
 
 PKCζ and Asthma. Pilar Martin’s group found increased PKCζ level during Th2 
differentiation of CD4+ T cells. A lack of PKCζ results in less secretion of Th2 cytokines 
both in vitro and in vivo, and an obvious impairment in the nuclear translocation and 
tyrosine phosphorylation of Stat6 activation. Most importantly, PKCζ-/- mice show 
significant inhibition of ovalbumin-induced allergic airway disease, which reveals that 
PKCζ might be a potential target for treatment of asthma [9]. 
 
 
 PKCζ and Human Osteoarthritic Chondrocytes. PKCζ was also reported to 
engage the regulation of interleukin (IL) -1beta -induced NF-κB signaling in human 
osteoarthritic (OA) chondrocytes, subsequently regulating the expression of downstream 
mediators of cartilage matrix degradation. It has been know that usually PKCζ level is 
up-regulated in OA patients [14].  
 
 
 PKCζ and Human Sepsis. Besides asthma and OA chondrocytes, PKCζ plays an 
important role in human peripheral blood monocytes and macrophages. In particular, 
Inhibition of PKCζ activity imparts both the activation of NF-κB and IL-1β gene 
expression stimulated by bacterial Lipopolysaccharide (LPS). PKCζ serves as a 
downstream signaling kinase of RhoA and upstream kinase of TAK1 in cytokine gene 
expression in human peripheral blood monocytes and macrophages [15].  
 
 
PKCζ and Diabetes 
 
 PKCζ is involved in insulin-mediated glucose uptake. Insulin stimulates glucose 
uptake to the plasma membrane by translocation of glucose transporter 4 (GLUT4). 
Peter’s group found that impaired glucose tolerance (IGT) is usually associated with 
impaired IRS-2-associated PI3 kinase activation and PKCζ expression, which may be 
responsible for the insulin resistance in IGT patients [16]. 
 
 
PKCζ and Obesity 
 
 Obesity has become a serious health problem in the United States: nearly 30% of 
Americans have obesity. Among all the states, West Virginia, Mississippi and Arkansas 
have the highest obesity rates at about 35%. If we look at the trend of obesity rates from 
1990 to 2014, the obesity rates were keeping increasing. Back to 1990, the average 
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obesity rate was about 12%. Right now it has increased more than twofold. Lots of 
research efforts have been done in the past few decades, while effective prevention and 
treatment of obesity are still lacking. A new finding reported by Dr. Mansbach’s group in 
department of medicine of University of Tennessee health science center suggested that 
PKCζ plays an important role in fat absorption (Figure 1-2). PKCζ phosphorylates 
Sarb1b with the help of ATP, disassembles this 4-protein complex into its components 
and releases liver fat binding protein (L-FABP). After that L-FABP is able to bind to 
intestinal endoplasmic reticulum (ER) and generate the pre-chylomicron transport 
vesicle, which then exerts its functions in fat absorption. Absence of PKCζ or ATP 
rendered no increase in ER binding or the production of pre-chylomicron transport 
vesicle. So our hypothesis is that, if we can selectively inhibitor PKC zeta, we are able to 
stabilize L-FABP and reduce fact absorption [17].  
 
 
Primarily Hit Identification for PKCζ Inhibitors 
 
 
Recent Advances in PKCζ Inhibitors and Related Challenges 
 
 Some hits from screening libraries or natural compound sources have been 
reported as PKCζ inhibitors, while up to now no PKCζ selective inhibitors have been 
reported. One major reason limiting the further exploitation of PKCζ as a novel drug 
target is the non-selectivity of the reported inhibitors towards the PKC isozymes. 
Although aPKCs possess distinctive sequences and structures at the ATP binding pockets 
compared with conventional PKCs and novel PKCs, which confers the possibility of 
developing specific inhibitors for aPKCs, the two isozymes of aPKCs, PKCι and PKCζ, 
share almost identical residues [18]. Therefore, PKCζ selective inhibitors haven’t been 
reported so far. Actually recently there were some efforts made aiming to discover the 
hits from virtual screening libraries or natural products. A series of 2-(6-phenyl-1H-
indazol-3-yl)-1H-benzo[d]imidazoles as selective PKCζ were reported and displayed 
good selectivity towards PKC isoforms, however they displayed inhibitory against a 
panel of other kinases as well [19]. Among all the compounds, JP-3-149, our previous lab 
member synthesized it and gave this name, showed the most potent activity against PKCζ 
with IC50 value of 5.6 nM (Figure 1-3). Jing Wu et al. discovered specific PKCζ 
inhibitor, PKCzI257.3, and evaluated its activity against EGF-induced breast cancer cell 
chemotaxis. Although it indeed displayed selectivity over conventional PKCs and novel 
PKCs, no data or studies have been showed that it is able to inhibit the most closely 
related isozyme PKCι [20]. Therefore, it is meaningful to discover a novel PKCζ scaffold 
with high activity and selectivity over PKC isozymes. In this pilot project thesis, we 
mainly used structured-based optimization and virtual screening to identify the hits with 
novel scaffolds for PKCζ inhibitors. 
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Figure 1-2. PKCζ is involved in fat absorption 
 
 
 
 
 
 
 
Figure 1-3. Structures of JP-3-149 and PKCzl257.3 
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Hit Identification for PKCζ Inhibitors 
 
 
 PKCζ Hit Identification by Structure Based Optimization. One way we 
adopted to identify the hits for PKCζ inhibition was to optimize the structures of reported 
compounds. Considering the highly potent activity of JP-3-149, we believe it would be a 
very good scaffold for us to modify. So what we did was basically moving this nitrogen 
in the imidazole to the 4 or 6 position on phenyl ring of the benzimidazole ring  
(Figure 1-4). Here are the structures of the compounds we came up with. The compounds 
were made by Dr. Dong-jin Hwang in Dr. Miller’s group. For the DJ-V-181, we kept the 
rest part of DJ-V-181 the same as what JP-3-149 has, and tried to see if this new scaffold 
would make any changes to the activity. DJ-V-155 has a phenol attached to 
benzimidazole ring instead of a N-methyl piperazine ring. DJ-V-185 has a 
methoxylphenol instead of just a phenol. Similarly, we designed and synthesized JW-1-
60A which possesses a methyl piperazine ring and a phenyl moiety at the other end. And 
from the molecular docking studies, JW-1-60A showed a very interesting binding mode, 
which is very similar to what JP-3-149 showed.  
 
 
 PKCζ Hit Identification by Virtual Screening. Recently, extensive reports 
showed that virtual screening has become a very popular technique at the initial stage of 
drug discovery due to its low cost and high efficiency. Lots of structures have been 
identified as novel leads for the drug targets using this technique. In this pilot project, a 
receptor-based virtual screening was performed to identify novel PKCζ inhibitors. About 
360 K compounds from a library of University of Cincinnati were used to undergo the 
virtual screening. The compounds were first filtered according to Lipinski’ Rule and drug 
like properties. Crystal structure 3EZR was downloaded from PDB and prepared. The 
Virtual Screening workflows includes glide HTVS, glide SP and glide XP. Only 10% of 
the compounds with the best docking scores were retained and advance into the next 
round. After these docking steps, twenty five compounds were picked and evaluated for 
their activity against PKCζ via enzyme based assay. 
 
 Among all the compounds selected and synthesized, compound JW-1-60A 
showed the most potency with an IC50 value close to 50 μM. Currently our project is still 
underway. A series of compounds based on the structure of JW-1-60A may further be 
designed, synthesized and investigated for their activity. Their selectivity against the 
general panel of kinases, including the most closely related isoenzyme PKCι will also be 
investigated. If they show selectivity towards the other kinases, cell assays and structure 
modifications will be performed as the next steps. 
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Figure 1-4. Structure optimization of JP-3-149 and molecular structures of DJ-
V-181, DJ-V-185, DJ-V-155 and JW-1-60A. 
ig re 1-4.  tr ct re o ti izatio  of J -3-149 a  olec lar str ct res of J-V-
181, DJ-V-185, DJ-V-155 and JW-1-60A. 
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CHAPTER 2.    METHODS 
 
 
ADP-GloTM Kinase Assay  
 
 Before testing the activity of the compounds, first we performed the method 
optimization for the ADP-GloTM Kinase Assay by optimizing the incubation time, 
reaction volume and the ratio of components. The activity of two PKCζ inhibitors, 
Go6850 and JP-3-149, was evaluated to see if the assay worked well (Figure 2-1). 
 
 Briefly, the activities of the compounds were measured by quantifying the amount 
of ADP produced during the reaction. The assay was based on the protocol provided by 
Promega with some modifications. 1 x Reaction buffer A supplemented with 50 μM DDT 
containing10 μL of kinase (10 ng), 5 μL of CREBtide (1 ng), 5 μL of pure ATP (50 μM, 
final concentration) and 5 μL of inhibitor (achieved through third-fold serial dilution) was 
used as the reaction buffer. The mixtures were incubated at the room temperature for 3 
hours or longer time. After that, 5 μL of ADP-GloTM reagent was added to each well and 
the mixtures were incubated at room temperature for 40 minutes or any desired time. 
Then, 10 μL of Kinase Detection Reagent was added to each well and the mixtures were 
incubated at room temperature for 30 to 60 minutes. The luminescence of the product 
was read with BioTek. The average background value was subtracted from the resulting 
values. 
 
 
Virtual Screening  
 
 
Ligand Preparation 
 
 A virtual drug discovery center library from the University of Cincinnati 
containing 362,910 compounds was used to undergo the virtual screening via VS 
Workflow module (Schrodinger, LLC, New York, NY, 2015). The compounds were first 
filtered prior to docking according to Lipinski’ Rule and drug like properties. As a result, 
the compounds containing some reactive functional groups, such as acyl halides, 
phosphinyl halides and disulfides were removed. After that, all the compounds were 
prepared and generated their ionization and tautomeric states with Epik at 7.0 ? 2.0 pH 
units. Conformers of the compounds were generated by OPLS_2005 force field, specially 
using the ConfGen conformational sampling algorithm. 
 
 
Receptor Preparation 
 
 X-ray structure 3EZR was downloaded from PDB and underwent the protein 
preparation. The grid of ATP binding site was defined based on the binding site of the 
reported active inhibitor [21]. Both the VdW radius scale factor and the charge scale 
factor were specified at 1.0 for the selected residues. After that four hydrogen bond  
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Figure 2-1. Dose-response curves of Go6850 and JP-3-149 inhibiting PKCζ 
phosphorylation 
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constraints were set. Specifically, the oxygen atoms of Glu 331, Val 333, Glu 300 and 
Asp 337 were picked in the Workspace. OPLS_2005 force field was used to computer 
partial charges. 
 
 
Molecular Docking 
 
 The prepared compounds and generated grid described above were specified in 
the Ligand section and Receptor grid section, respectively. OPLS2001 was selected as 
force field with post-docking minimizations. Docking with Glide HTVS, Glide SP and 
Glide XP were all selected. And in each docking method, flexible docking was chosen 
and at least 3 constrains among total 4 constrains were used for the grid during docking 
process. Only 10% of the compounds with the best docking scores were allowed to be 
kept and advance into the next round. All the good scoring states of each ligand docked 
with Glide HTVS and SP were retained, while only the best scoring pose was retained for 
compounds docked with Glide XP. 
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CHAPTER 3.    RESULTS 
 
 
Activity of DJ-V-181, DJ-V-155 and DJ-V-185  
 
 After the assay worked, we tested the activity of these three compounds. To our 
surprise, none of them showed significant activity at 10 or 3 μM against PKC-zeta 
(Figure 3-1). The positive control, JP-3-149, showed almost 100% inhibition 
 
 Figure 3-2 shows the binding mode of JP-3-149. This nitrogen in the imidazole of 
JP-3-149 does form hydrogen bond with Tyr332, so we think it may be very critical for 
its binding and this might explain why DJ-V-181, DJ-V-155 and DJ-V-185 didn’t show 
activity against PKC-zeta at 10 or 3 μM.  
 
 Based on this conclusion and the molecular studies, another four compounds were 
designed. Instead of removing the nitrogen away from the indazole ring, we are trying to 
add an extra nitrogen to the benzimidazole. Besides, some modifications on the methyl 
piperazine ring will also be conducted to improve the hydrogen bindings (Figure 3-3). 
 
 
Activity of JW-1-60A  
 
 As Figure 3-4 shows, at 10 μM JW-1-60A didn’t show any inhibition either, 
while at 30 μM and 100 μM, we can see its significant inhibition against PKC-ζ. The 
binding mode of JW-1-60A was examined by molecular modeling studies using 
Schrodinger Molecular Modeling Suite 2015. Figure 3-5 shows the overall binding 
modes of JW-1-60A (orange tube model) and JP-3-149 (purple tube model) in the ATP-
binding site pocket of the PKCζ (3EZV). In particular, their piperazine rings approach 
deep into the hinge region. At the other end, their phenyl moieties place at almost the 
same location. We believe their similar binding modes partially explain the activity of 
JW-1-60A. They both extend from the hinge region and reach another pocket formed 
basically by two loops, and band in the middle. As reported by the John’s group, JP-3-
149 would form one hydrogen bond with Asp 331 and two hydrogen bonds with Val 332, 
respectively. An additional hydrogen bond between its phenol and Glu 300 of helix C 
was also observed as well. However, JW-1-60A shows less interactions compared with 
JP-3-149. Only one hydrogen bond with Tyr 332 is formed. Interestingly, the overall 
location of JW-1-60A is shallower inside the pocket than the location of JP-3-149, which 
we believe might be another factor leading to the worse activity of JW-1-60A than JP-3-
149.  
 
 
Activity of 25 Compounds Selected from Virtual Screening  
 
 Figure 3-6 shows the structures of the selected compounds. Unfortunately, none 
of the compound selected from Virtual Screening showed significant activity against 
PKCζ at 10 μM or 3 μM. The positive control used was Go6850 (Figure 3-7).  
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Figure 3-2. Molecular binding mode of JP-3-149 
 
 
  
Figure 3-1. Inhibition of PKCζ by DJ-V-181, 155 and 185 at 3 μM and 10 μM 
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Figure 3-3.  The structures of DJ-1, DJ-2, DJ-3, DJ-4 
 
 
 
 
 
 
 
 
 
  
Figure 3-4. Dose-response curves of JW-1-60A inhibiting PKCζ 
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Figure 3-5. Superposition of JP-3-149 and JW-1-60A 
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Figure 3-6. Molecular structures of compounds selected from virtual screening 
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Figure 3-7. The screen results of the 25 compounds selected from virtual 
screening 
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CHAPTER 4.    DISCUSSION 
 
 
 Novel PKCζ inhibitor, JW-1-60A, was designed and synthesized. JW-1-60A 
showed moderate activity against PKCζ. Molecular modeling studies were performed to 
examine the binding of JW-1-60A in PKCζ crystal structure. Based on the binding mode 
of JW-1-60A and JP-3-149 (Figure 3-5), we came up with some ideas about future 
modifications of JW-1-60A. Like we can change the isopropyl phenyl to phenol to take 
advantage of the interactions with Glu 300. Or we can incorporate an indazole ring to the 
linker in order to form hydrogen binds with Val 333 and Glu 331, and also make the 
structure more rigid. 
 
 The binding mode of JW-1-60A was very close to the binding mode of JP-3-149, 
which might partially explain the moderate activity of JW-1-60A. In summary, JW-1-
60A represents a novel scaffold of PKCζ inhibitors, which might be used to generate a 
series of its analogs with potent activity and high in the future. Furthermore, this 
compound will be investigated its selectivity against the other isoforms of PKC family 
and other kinases later. 
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